MEI Pharma Inc. (NASDAQ: (MEIP) stock plunged by 6.13% at last close whereas the MEIP stock price gained by 8.16% in the after-hours trading session. MEI Pharma is a late-stage pharmaceutical business dedicated to the development of novel cancer medicines.
MEIP stock’ Current Update
MEI Pharma has stated that on Tuesday, November 30, 2021, the company will offer a live investor and analyst webcast to discuss data from the ongoing worldwide Phase 2 TIDAL project, which is testing zandelisib in patients with relapsed or refractory follicular lymphoma. The webcast will also include a company update and an overview of the zandelisib program.
Recent Past Development
Mr. Sujay Kango has been appointed to MEI Pharma’s board of directors, beginning November 22, 2021.
Mr. Sujay Kango is a seasoned executive who has worked in the pharmaceutical and biotechnology sectors for over 25 years. He has held top management positions in which he was responsible for the development of commercial infrastructures and teams as well as the launch of various worldwide products. He joined Acceleron Pharma in 2018 as executive vice president and chief commercial officer, where he was in charge of building the company’s luspatercept commercial presence in North America. Mr. Kango has also overseen many worldwide pharmaceutical launches in oncology-hematology, rare illnesses, immunology, and virology, among other therapeutic areas.
Christine A. White, chairman of the board, MEI Pharma commented that,
They are delighted to welcome Sujay to the MEI board of directors, as the firm pursues its objective of bringing novel cancer therapeutics to patients. They are excited to gain from Sujay’s over 25 years of industry knowledge and experience as MEI prepares to move to a commercial-stage firm and build its trial pipeline.
Sujay Kango stated that,
He is excited to be a part of the board of directors at this critical juncture to help MEI develop into a commercial-stage company. He is excited to be a part of MEI’s continued growth and success as it pursues its aim of providing novel cancer medicines to patients.
